Clarity Pharmaceuticals Limited

Australie

Retour au propriétaire

1-46 de 46 pour Clarity Pharmaceuticals Limited Trier par
Recheche Texte
Affiner par
Type PI
        Brevet 40
        Marque 6
Juridiction
        États-Unis 31
        International 12
        Canada 3
Date
2025 février 1
2025 (AACJ) 3
2024 18
2023 5
2022 4
Voir plus
Classe IPC
A61K 51/04 - Composés organiques 28
A61K 51/08 - Peptides, p. ex. protéines 25
C07D 487/08 - Systèmes pontés 14
A61P 35/00 - Agents anticancéreux 13
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier 9
Voir plus
Classe NICE
05 - Produits pharmaceutiques, vétérinaires et hygièniques 6
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 4
06 - Métaux communs et minerais; objets en métal 4
10 - Appareils et instruments médicaux 4
20 - Meubles et produits décoratifs 4
Voir plus
Statut
En Instance 19
Enregistré / En vigueur 27

1.

RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF

      
Numéro d'application 18943277
Statut En instance
Date de dépôt 2024-11-11
Date de la première publication 2025-02-27
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Zia, Nicholas Alan
  • Donnelly, Paul Stephen

Abrégé

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

  • C07D 487/08 - Systèmes pontés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 33/34 - CuivreSes composés
  • A61K 51/04 - Composés organiques
  • A61K 51/06 - Composés macromoléculaires
  • C07F 1/00 - Composés contenant des éléments des groupes 1 ou 11 du tableau périodique
  • C07F 1/08 - Composés du cuivre

2.

COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER

      
Numéro d'application 18713134
Statut En instance
Date de dépôt 2022-11-24
Date de la première publication 2025-01-09
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Harris, Matthew John
  • Van Dam, Ellen Marianne
  • Biggin, Colin

Abrégé

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to PSMA, compositions thereof and uses thereof in methods of treatment.

Classes IPC  ?

  • C07K 5/107 - Tétrapeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p. ex. Phe, Tyr
  • A61K 51/08 - Peptides, p. ex. protéines

3.

METHODS FOR THE DIAGNOSIS AND/OR TREATMENT OF NEUROENDOCRINE CANCERS

      
Numéro d'application AU2024050685
Numéro de publication 2025/000035
Statut Délivré - en vigueur
Date de dépôt 2024-06-27
Date de publication 2025-01-02
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Parker, Michelle
  • Lengyelova, Eva
  • Hedt, Amos
  • Biggin, Colin

Abrégé

The present invention relates to methods of diagnosis and/or radiotherapy, comprising the administration of a compound of Formula (I) and a 64Cu /67Cu radioisotope to deliver a targeted dose of radiation for the diagnosis and treatment of a neuroendocrine cancer, particularly neuroblastoma in children.

Classes IPC  ?

4.

METHODS FOR THE DIAGNOSIS AND/OR TREATMENT OF PROSTATE CANCER

      
Numéro d'application AU2024050504
Numéro de publication 2024/234061
Statut Délivré - en vigueur
Date de dépôt 2024-05-17
Date de publication 2024-11-21
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s) Lengyelova, Eva

Abrégé

The present invention relates generally to methods of diagnosing and/or treating of a cancer associated with overexpression of a PSMA membrane protein, or for reducing PSA levels in a subject. The present invention also relates to radiotherapeutic methods comprising the administration to a subject in need thereof a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a radioisotope to deliver a dose of radiation to a specific site for the treatment of the cancer.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/08 - Solutions
  • A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
  • A61K 51/04 - Composés organiques
  • A61P 35/00 - Agents anticancéreux

5.

RADIOPHARMACEUTICALS, METHODS FOR THE PRODUCTION THEREOF, AND USES IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES

      
Numéro d'application 18684582
Statut En instance
Date de dépôt 2022-08-16
Date de la première publication 2024-11-21
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Donnelly, Paul Stephen
  • Ironside, Michael David

Abrégé

The present invention relates to compounds that can complex a radionuclide and formulations and kits comprising compounds that can complex a radionuclide. The compounds, formulations and kits are of use in radiotherapy and diagnostic imaging.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
  • C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

6.

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING

      
Numéro d'application 18409431
Statut En instance
Date de dépôt 2024-01-10
Date de la première publication 2024-08-29
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Van Dam, Ellen Marianne
  • Jeffery, Charmaine Marie

Abrégé

The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging.

Classes IPC  ?

  • A61K 51/04 - Composés organiques
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support
  • A61K 51/08 - Peptides, p. ex. protéines

7.

TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTION

      
Numéro d'application 18597131
Statut En instance
Date de dépôt 2024-03-06
Date de la première publication 2024-08-22
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Zia, Nicholas Alan

Abrégé

The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody. The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.

Classes IPC  ?

8.

METHODS FOR THE DETECTION AND DIAGNOSIS OF CANCERS ASSOCIATED WITH OVEREXPRESSION OF A PSMA RECEPTOR

      
Numéro d'application AU2024050097
Numéro de publication 2024/168386
Statut Délivré - en vigueur
Date de dépôt 2024-02-14
Date de publication 2024-08-22
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Lengyelova, Eva
  • Miller, Robert
  • Emmett, Louise

Abrégé

The present invention relates to methods for the detection and diagnosis of a cancer related to overexpression of prostate-specific membrane antigen (PSMA) by administering a dose of between about 100MBq to about 300 MBq of a 64Cu-labled sarcophagine compound, Sar-bisPSMA, and PET imaging the patient. This method allows for images of greater resolution, even at cancer sites having a lower density of PSMA, such as a secondary lesion.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/08 - Solutions
  • A61K 47/02 - Composés inorganiques
  • A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
  • A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
  • A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases

9.

CLARITY PHARMACEUTICALS

      
Numéro de série 98641771
Statut En instance
Date de dépôt 2024-07-10
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 06 - Métaux communs et minerais; objets en métal
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 10 - Appareils et instruments médicaux
  • 20 - Meubles et produits décoratifs
  • 39 - Services de transport, emballage et entreposage; organisation de voyages
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Retail store services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; wholesale services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; import-exports agencies in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; distribution of advertising materials and samples in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; business administration; business project management; advertising, marketing and promotional services; administration of businesses; business planning; administration relating to business planning; administration relating to marketing; business advisory services; business advisory services relating to product development; business advisory services relating to the management of businesses; business advice relating to advertising; dissemination of advertising material; dissemination of advertising matter; disseminating business, consumer, or commercial information in the field of pharmaceuticals, production and consumption; advertising; consulting services relating to marketing, advertising, promotion, brand development, business strategy, business and brand design, business communications and tracking and analysis of market trends; analysing and compiling business data for marketing intelligence purposes; business analysis services; business administration and management of shareholder and investor relations; providing shareholder business or commercial record keeping and business information and analysis; businesses development, management and operation services in the pharmaceutical and healthcare industries; intermediary business services relating to the commercialisation of goods; technology transfer services (business services); promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; marketing of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business intermediary services for the sale and purchase of goods and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business information services; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing advertising information featuring goods and services of others for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma via an on-line searchable database; business advisory services relating to the commercialisation of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; chemical products for industrial, scientific and research purposes, namely, chemical reagents and chemical preparations for industrial, scientific and research purposes; fissionable chemical elements, namely, chemicals for use in industry and science and chemical substances for analyses in laboratories, other than for medical or veterinary purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive standard preparations in the nature of radionuclides and radioactive elements for the calibration of apparatus and machinery; diagnostic preparations, other than for medical or veterinary purposes; isotopes for industrial purposes; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical reagents, other than for medical or veterinary purposes; chemicals for use in the manufacture of radiopharmaceutical products; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anti-carcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for the treatment of cancers; pharmaceutical preparations and substances for diagnosis of cancers; pharmaceutical preparations and substances for therapy and treatment of cancers; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations for pharmaceutical use, namely, for the diagnosis and treatment of cancers; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; pharmaceutical preparations for the diagnosis of cancers; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemical preparations for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; reagents for medical purposes; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances in the nature of contrasting agents for medical imaging; diagnostic scanning reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemical preparations and reagents for medical purposes Containers of metal for storage of goods; containers of metal for medical waste; containers of metal for storing and transporting radioactive elements, products and materials; containers of metal for storing and transporting radioactive products; containers of metal for storing and transporting medical goods, apparatus and devices; containers of metal for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; parts and fittings for the aforesaid goods Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radioprotectors; custom manufacture of radiotherapy apparatus, devices and instruments; custom manufacture of apparatus, devices and instruments for medical purposes; custom manufacture of apparatus, devices and instruments for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; instruments and apparatus for immunotherapy and immuno-diagnostics; medical devices, namely, blood analyzers; diagnostic devices for medical purposes, namely, medical imaging and detection devices; electrodes for medical purposes; injection syringes; instrument cases fitted for medical instruments for use by doctors and surgeons; special cases fitted for medical instruments; masks for medical staff, namely, surgical masks and protective face masks for medical use; pumps for medical purposes, namely, vacuum pumps for medical purposes; radiological apparatus for medical purposes; special containers for medical waste; storage and transport containers especially adapted for protection against ionising radiation for medical use; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; medical containers especially designed to maintain a consistent internal temperature; temperature controlled packaging specifically adapted for the transportation of pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; temperature controlled medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; refrigerated medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood, blood products, medical supplies, medical products, bio-technological products and diagnostic products; devices for detecting ionising radiation for medical use; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; nuclear medical tomographic scanner; diagnostic imaging apparatus for nuclear medicine; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; medical apparatus for the treatment of cancer; diagnostic imaging apparatus for medical use; pharmaceutical instruments, namely, radiological apparatus for medical purposes, medical apparatus for the treatment of cancer and diseases associated with cellular proliferation, and imaging apparatus for medical use for diagnosing medical conditions; applicators for pharmaceutical preparations, namely, applicators for pharmaceutical preparations sold without medication; medical apparatus for administering radiopharmaceutical diagnostic products; parts and fittings for the aforesaid goods Non-metallic containers, namely, containers for industrial and commercial liquids not made of metal; non-metallic containers for storing and transporting radioactive elements, products and materials; non-metallic containers for storing and transporting radioactive products; non-metallic containers for storing and transporting medical goods, apparatus and devices; non-metallic containers for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; structural foam containers for storage or transport; containers for transport, not of metal; parts and fittings for the aforesaid goods Supply chain logistics and reverse logistics services, namely, storage, transportation and delivery of goods for others by air, rail, ship or truck; supply chain logistics and reverse logistics services, namely, the storage, transportation and delivery of pharmaceuticals, radiopharmaceuticals, pharmaceutical and radiopharmaceuticals products for others by air, rail, ship or truck; packaging for transportation of clinical, pharmaceutical, radiopharmaceutical and health care products to the order and specification of others; leasing of temperature controlled cases for storage and transportation purposes; rental of insulated shipping containers for transporting temperature controlled materials; rental of insulated shipping containers for transporting room temperature, chilled, and frozen materials; providing information, consultancy and advisory services in relation to the aforementioned services Pharmaceutical, medicinal, veterinary and therapeutic research and development; pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services, namely, scientific research, analysis, testing, and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for medical use; scientific laboratory services; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; scientific research in the nature of conducting clinical trials in the field of oncology; scientific research in the nature of conducting clinical trials for others, namely, conducting phase clinical trials with target radiopharmaceuticals; medical and scientific research, namely, conducting clinical and pre-clinical trial services for others; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; research services in the fields of magnetic resonance and molecular imaging; medical research services relating to the development of radiotherapeutics and precision oncology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing and analysis of medical images; pathology services in support of drug development; pathology services for preclinical biomarker discovery research and clinical trials; hosting of a medical imaging analysis and visualization platform through a global computer network; hosting of a database of medical images; software as a service (SaaS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals, radiopharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blind independent central review of radiology images in the medical research and clinical trial setting; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in pharmaceutical and radiopharmaceutical drug research in the field of drug discovery; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; providing nondownloadable web-based computer software for database management in the fields of medical research, medical imaging, pharmaceutical, radiopharmaceutical and biotechnology research; research and development of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, medicines, pharmaceutical packaging and drug delivery technologies; research and development of new products for others; product development consultation; product research services, including, providing analytical testing, biosafety testing, reporting and laboratory services for others; preparation of scientific reports; scientific and technical consulting and research services for the pharmaceutical industry; consultation in the field of pharmaceutical drug delivery and dosage technologies; scientific and medical research and product design in relation to positron emission tomography imaging; scientific and medical research and product design in relation to single photon emission tomography imaging; design and development services; design and development of containers for the storage and transport of radioactive materials, radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; medical and scientific research in relation to disease diagnosis; scientific and medical research in relation to molecular imaging; development of molecular imaging products, development of non-medical molecular imaging services; diagnostic imaging for scientific purposes; scientific imaging services; medical laboratory services; medical and pharmacological research services; providing information, advisory and consultancy services in relation to the aforementioned services Provision of medical, health care, wellness and nutrition services; provision of medical, health care, wellness and nutrition advice services in relation to the prevention, treatment, prophylaxis and management of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood- borne tumours, leukemia and melanoma; medical counseling services in the field of treatment, prophylaxis or prevention of medical conditions; mental health therapy services, namely, psychedelic therapy; psychotherapy; medical treatment and therapy incorporating virtual reality; pharmaceutical advisory services; alternative medicine services; providing information, consultancy and advisory services in relation to the aforementioned services Licensing of technology, namely, patent and confidential information licensing of radiopharmaceutical preparations, technologies and apparatus; patent licensing; licensing of intellectual property; legal services relating to the exploitation of intellectual property rights; providing information, consultancy and advisory services in relation to the aforementioned services

10.

Miscellaneous Design

      
Numéro de série 98641779
Statut En instance
Date de dépôt 2024-07-10
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 06 - Métaux communs et minerais; objets en métal
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 10 - Appareils et instruments médicaux
  • 20 - Meubles et produits décoratifs
  • 39 - Services de transport, emballage et entreposage; organisation de voyages
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Retail store services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; wholesale services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; import-exports agencies in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; distribution of advertising materials and samples in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; business administration; business project management; advertising, marketing and promotional services; administration of businesses; business planning; administration relating to business planning; administration relating to marketing; business advisory services; business advisory services relating to product development; business advisory services relating to the management of businesses; business advice relating to advertising; dissemination of advertising material; dissemination of advertising matter; disseminating business, consumer, or commercial information in the field of pharmaceuticals, production and consumption; advertising; consulting services relating to marketing, advertising, promotion, brand development, business strategy, business and brand design, business communications and tracking and analysis of market trends; analysing and compiling business data for marketing intelligence purposes; business analysis services; business administration and management of shareholder and investor relations; providing shareholder business or commercial record keeping and business information and analysis; businesses development, management and operation services in the pharmaceutical and healthcare industries; intermediary business services relating to the commercialisation of goods; technology transfer services (business services); promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; marketing of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business intermediary services for the sale and purchase of goods and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business information services; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing advertising information featuring goods and services of others for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma via an on-line searchable database; business advisory services relating to the commercialisation of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; chemical products for industrial, scientific and research purposes, namely, chemical reagents and chemical preparations for industrial, scientific and research purposes; fissionable chemical elements, namely, chemicals for use in industry and science and chemical substances for analyses in laboratories, other than for medical or veterinary purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive standard preparations in the nature of radionuclides and radioactive elements for the calibration of apparatus and machinery; diagnostic preparations, other than for medical or veterinary purposes; isotopes for industrial purposes; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical reagents, other than for medical or veterinary purposes; chemicals for use in the manufacture of radiopharmaceutical products; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anti-carcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for the treatment of cancers; pharmaceutical preparations and substances for diagnosis of cancers; pharmaceutical preparations and substances for therapy and treatment of cancers; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations for pharmaceutical use, namely, for the diagnosis and treatment of cancers; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; pharmaceutical preparations for the diagnosis of cancers; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemical preparations for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; reagents for medical purposes; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances in the nature of contrasting agents for medical imaging; diagnostic scanning reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemical preparations and reagents for medical purposes Containers of metal for storage of goods; containers of metal for medical waste; containers of metal for storing and transporting radioactive elements, products and materials; containers of metal for storing and transporting radioactive products; containers of metal for storing and transporting medical goods, apparatus and devices; containers of metal for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; parts and fittings for the aforesaid goods Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radioprotectors; custom manufacture of radiotherapy apparatus, devices and instruments; custom manufacture of apparatus, devices and instruments for medical purposes; custom manufacture of apparatus, devices and instruments for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; instruments and apparatus for immunotherapy and immuno-diagnostics; medical devices, namely, blood analyzers; diagnostic devices for medical purposes, namely, medical imaging and detection devices; electrodes for medical purposes; injection syringes; instrument cases fitted for medical instruments for use by doctors and surgeons; special cases fitted for medical instruments; masks for medical staff, namely, surgical masks and protective face masks for medical use; pumps for medical purposes, namely, vacuum pumps for medical purposes; radiological apparatus for medical purposes; special containers for medical waste; storage and transport containers especially adapted for protection against ionising radiation for medical use; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; medical containers especially designed to maintain a consistent internal temperature; temperature controlled packaging specifically adapted for the transportation of pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; temperature controlled medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; refrigerated medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood, blood products, medical supplies, medical products, bio-technological products and diagnostic products; devices for detecting ionising radiation for medical use; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; nuclear medical tomographic scanner; diagnostic imaging apparatus for nuclear medicine; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; medical apparatus for the treatment of cancer; diagnostic imaging apparatus for medical use; pharmaceutical instruments, namely, radiological apparatus for medical purposes, medical apparatus for the treatment of cancer and diseases associated with cellular proliferation, and imaging apparatus for medical use for diagnosing medical conditions; applicators for pharmaceutical preparations, namely, applicators for pharmaceutical preparations sold without medication; medical apparatus for administering radiopharmaceutical diagnostic products; parts and fittings for the aforesaid goods Non-metallic containers, namely, containers for industrial and commercial liquids not made of metal; non-metallic containers for storing and transporting radioactive elements, products and materials; non-metallic containers for storing and transporting radioactive products; non-metallic containers for storing and transporting medical goods, apparatus and devices; non-metallic containers for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; structural foam containers for storage or transport; containers for transport, not of metal; parts and fittings for the aforesaid goods Supply chain logistics and reverse logistics services, namely, storage, transportation and delivery of goods for others by air, rail, ship or truck; supply chain logistics and reverse logistics services, namely, the storage, transportation and delivery of pharmaceuticals, radiopharmaceuticals, pharmaceutical and radiopharmaceuticals products for others by air, rail, ship or truck; packaging for transportation of clinical, pharmaceutical, radiopharmaceutical and health care products to the order and specification of others; leasing of temperature controlled cases for storage and transportation purposes; rental of insulated shipping containers for transporting temperature controlled materials; rental of insulated shipping containers for transporting room temperature, chilled, and frozen materials; providing information, consultancy and advisory services in relation to the aforementioned services Pharmaceutical, medicinal, veterinary and therapeutic research and development; pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services, namely, scientific research, analysis, testing, and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for medical use; scientific laboratory services; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; scientific research in the nature of conducting clinical trials in the field of oncology; scientific research in the nature of conducting clinical trials for others, namely, conducting phase clinical trials with target radiopharmaceuticals; medical and scientific research, namely, conducting clinical and pre-clinical trial services for others; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; research services in the fields of magnetic resonance and molecular imaging; medical research services relating to the development of radiotherapeutics and precision oncology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing and analysis of medical images; pathology services in support of drug development; pathology services for preclinical biomarker discovery research and clinical trials; hosting of a medical imaging analysis and visualization platform through a global computer network; hosting of a database of medical images; software as a service (SaaS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals, radiopharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blind independent central review of radiology images in the medical research and clinical trial setting; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in pharmaceutical and radiopharmaceutical drug research in the field of drug discovery; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; providing nondownloadable web-based computer software for database management in the fields of medical research, medical imaging, pharmaceutical, radiopharmaceutical and biotechnology research; research and development of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, medicines, pharmaceutical packaging and drug delivery technologies; research and development of new products for others; product development consultation; product research services, including, providing analytical testing, biosafety testing, reporting and laboratory services for others; preparation of scientific reports; scientific and technical consulting and research services for the pharmaceutical industry; consultation in the field of pharmaceutical drug delivery and dosage technologies; scientific and medical research and product design in relation to positron emission tomography imaging; scientific and medical research and product design in relation to single photon emission tomography imaging; design and development services; design and development of containers for the storage and transport of radioactive materials, radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; medical and scientific research in relation to disease diagnosis; scientific and medical research in relation to molecular imaging; development of molecular imaging products, development of non-medical molecular imaging services; diagnostic imaging for scientific purposes; scientific imaging services; medical laboratory services; medical and pharmacological research services; providing information, advisory and consultancy services in relation to the aforementioned services Provision of medical, health care, wellness and nutrition services; provision of medical, health care, wellness and nutrition advice services in relation to the prevention, treatment, prophylaxis and management of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood- borne tumours, leukemia and melanoma; medical counseling services in the field of treatment, prophylaxis or prevention of medical conditions; mental health therapy services, namely, psychedelic therapy; psychotherapy; medical treatment and therapy incorporating virtual reality; pharmaceutical advisory services; alternative medicine services; providing information, consultancy and advisory services in relation to the aforementioned services Licensing of technology, namely, patent and confidential information licensing of radiopharmaceutical preparations, technologies and apparatus; patent licensing; licensing of intellectual property; legal services relating to the exploitation of intellectual property rights; providing information, consultancy and advisory services in relation to the aforementioned services

11.

SAR-BISPSMA

      
Numéro de série 98641784
Statut En instance
Date de dépôt 2024-07-10
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for the treatment of cancers; pharmaceutical preparations and substances for diagnosis of cancers; pharmaceutical preparations and substances for therapy and treatment of cancers; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations for pharmaceutical use, namely, for the diagnosis and treatment of cancers; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; pharmaceutical preparations for the diagnosis of cancers; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemical preparations for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; reagents for medical purposes; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances in the nature of contrasting agents for medical imaging; diagnostic scanning reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemical preparations and reagents for medical purposes

12.

SARTATE

      
Numéro de série 98641789
Statut En instance
Date de dépôt 2024-07-10
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceuticals and other preparations for medical and veterinary purposes, namely, radioactive pharmaceuticals and radiopharmaceutical preparations for the imaging, diagnosis, treatment and therapy of tumors and cancer

13.

CLARITY

      
Numéro de série 98641763
Statut En instance
Date de dépôt 2024-07-10
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 06 - Métaux communs et minerais; objets en métal
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 10 - Appareils et instruments médicaux
  • 20 - Meubles et produits décoratifs
  • 39 - Services de transport, emballage et entreposage; organisation de voyages
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Retail store services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; wholesale services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; import-exports agencies in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; distribution of advertising materials and samples in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; business administration; business project management; advertising, marketing and promotional services; administration of businesses; business planning; administration relating to business planning; administration relating to marketing; business advisory services; business advisory services relating to product development; business advisory services relating to the management of businesses; business advice relating to advertising; dissemination of advertising material; dissemination of advertising matter; disseminating business, consumer, or commercial information in the field of pharmaceuticals, production and consumption; advertising; consulting services relating to marketing, advertising, promotion, brand development, business strategy, business and brand design, business communications and tracking and analysis of market trends; analysing and compiling business data for marketing intelligence purposes; business analysis services; business administration and management of shareholder and investor relations; providing shareholder business or commercial record keeping and business information and analysis; businesses development, management and operation services in the pharmaceutical and healthcare industries; intermediary business services relating to the commercialisation of goods; technology transfer services (business services); promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; marketing of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business intermediary services for the sale and purchase of goods and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business information services; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing advertising information featuring goods and services of others for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma via an on-line searchable database; business advisory services relating to the commercialisation of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; chemical products for industrial, scientific and research purposes, namely, chemical reagents and chemical preparations for industrial, scientific and research purposes; fissionable chemical elements, namely, chemicals for use in industry and science and chemical substances for analyses in laboratories, other than for medical or veterinary purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive standard preparations in the nature of radionuclides and radioactive elements for the calibration of apparatus and machinery; diagnostic preparations, other than for medical or veterinary purposes; isotopes for industrial purposes; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical reagents, other than for medical or veterinary purposes; chemicals for use in the manufacture of radiopharmaceutical products; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anticarcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for the treatment of cancers; pharmaceutical preparations and substances for diagnosis of cancers; pharmaceutical preparations and substances for therapy and treatment of cancers; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; radiopharmaceutical preparations for the treatment and diagnosis of cancers radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radioisotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radioisotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations for pharmaceutical use, namely, for chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; pharmaceutical preparations for the diagnosis of cancers; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemical preparations for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radioisotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in-vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; reagents for medical purposes; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in-vivo imaging; pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radioisotope markers; diagnostic radiopharmaceutical preparations and radioisotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances in the nature of contrasting agents for medical imaging; diagnostic scanning reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemical preparations reagents for medical purposes Containers of metal for storage of goods; containers of metal for medical waste; containers of metal for storing and transporting radioactive elements, products and materials; containers of metal for storing and transporting radioactive products; containers of metal for storing and transporting medical goods, apparatus and devices; containers of metal for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; parts and fittings for the aforesaid goods Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radioprotectors; custom manufacture of radiotherapy apparatus, devices and instruments; custom manufacture of apparatus, devices and instruments for medical purposes; custom manufacture of apparatus, devices and instruments for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; instruments and apparatus for immunotherapy and immuno-diagnostics; medical devices, namely, blood analyzers; diagnostic devices for medical purposes, namely, medical imaging and detection devices; electrodes for medical purposes; injection syringes; instrument cases fitted for medical instruments for use by doctors and surgeons; special cases fitted for medical instruments; masks for medical staff, namely, surgical masks and protective face masks for medical use; pumps for medical purposes, namely, vacuum pumps for medical purposes; radiological apparatus for medical purposes; special containers for medical waste; storage and transport containers especially adapted for protection against ionising radiation for medical use; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; medical containers especially designed to maintain a consistent internal temperature; temperature controlled packaging specifically adapted for the transportation of pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; temperature controlled medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; refrigerated medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood, blood products, medical supplies, medical products, bio-technological products and diagnostic products; devices for detecting ionising radiation for medical use; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; nuclear medical tomographic scanner; diagnostic imaging apparatus for nuclear medicine; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; medical apparatus for the treatment of cancer; diagnostic imaging apparatus for medical use; pharmaceutical instruments, namely, radiological apparatus for medical purposes, medical apparatus for the treatment of cancer and diseases associated with cellular proliferation, and imaging apparatus for medical use for diagnosing medical conditions; applicators for pharmaceutical preparations, namely, applicators for pharmaceutical preparations sold without medication; medical apparatus for administering radiopharmaceutical diagnostic products; parts and fittings for the aforesaid goods Non-metallic containers, namely, containers for industrial and commercial liquids not made of metal; non-metallic containers for storing and transporting radioactive elements, products and materials; non-metallic containers for storing and transporting radioactive products; non-metallic containers for storing and transporting medical goods, apparatus and devices; non-metallic containers for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; structural foam containers for storage or transport; containers for transport, not of metal; parts and fittings for the aforesaid goods Supply chain logistics and reverse logistics services, namely, storage, transportation and delivery of goods for others by air, rail, ship or truck; supply chain logistics and reverse logistics services, namely, the storage, transportation and delivery of pharmaceuticals, radiopharmaceuticals, pharmaceutical and radiopharmaceuticals products for others by air, rail, ship or truck; packaging for transportation of clinical, pharmaceutical, radiopharmaceutical and health care products to the order and specification of others; leasing of temperature controlled cases for storage and transportation purposes; rental of insulated shipping containers for transporting temperature controlled materials; rental of insulated shipping containers for transporting room temperature, chilled, and frozen materials; providing information, consultancy and advisory services in relation to the aforementioned services Pharmaceutical, medicinal, veterinary and therapeutic research and development; pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services, namely, scientific research, analysis, testing, and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for medical use; scientific laboratory services; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; scientific research in the nature of conducting clinical trials in the field of oncology; scientific research in the nature of conducting clinical trials for others, namely, conducting phase clinical trials with target radiopharmaceuticals; medical and scientific research, namely, conducting clinical and pre-clinical trial services for others; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; research services in the fields of magnetic resonance and molecular imaging; medical research services relating to the development of radiotherapeutics and precision oncology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing and analysis of medical images; pathology services in support of drug development; pathology services for preclinical biomarker discovery research and clinical trials; hosting of a medical imaging analysis and visualization platform through a global computer network; hosting of a database of medical images; software as a service (SaaS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals, radiopharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blind independent central review of radiology images in the medical research and clinical trial setting; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in pharmaceutical and radiopharmaceutical drug research in the field of drug discovery; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; providing nondownloadable web-based computer software for database management in the fields of medical research, medical imaging, pharmaceutical, radiopharmaceutical and biotechnology research; research and development of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, medicines, pharmaceutical packaging and drug delivery technologies; research and development of new products for others; product development consultation; product research services, including, providing analytical testing, biosafety testing, reporting and laboratory services for others; preparation of scientific reports; scientific and technical consulting and research services for the pharmaceutical industry; consultation in the field of pharmaceutical drug delivery and dosage technologies; scientific and medical research and product design in relation to positron emission tomography imaging; scientific and medical research and product design in relation to single photon emission tomography imaging; design and development services; design and development of containers for the storage and transport of radioactive materials, radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; medical and scientific research in relation to disease diagnosis; scientific and medical research in relation to molecular imaging; development of molecular imaging products, development of non-medical molecular imaging services; diagnostic imaging for scientific purposes; scientific imaging services; medical laboratory services; medical and pharmacological research services; providing information, advisory and consultancy services in relation to the aforementioned services Provision of medical, health care, wellness and nutrition services; provision of medical, health care, wellness and nutrition advice services in relation to the prevention, treatment, prophylaxis and management of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood- borne tumours, leukemia and melanoma; medical counseling services in the field of treatment, prophylaxis or prevention of medical conditions; mental health therapy services, namely, psychedelic therapy; psychotherapy; medical treatment and therapy incorporating virtual reality; pharmaceutical advisory services; alternative medicine services; providing information, consultancy and advisory services in relation to the aforementioned services Licensing of technology, namely, patent and confidential information licensing of radiopharmaceutical preparations, technologies and apparatus; patent licensing; licensing of intellectual property; legal services relating to the exploitation of intellectual property rights; providing information, consultancy and advisory services in relation to the aforementioned services

14.

CLARITY PHARMACEUTICALS

      
Numéro de série 98641775
Statut En instance
Date de dépôt 2024-07-10
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 06 - Métaux communs et minerais; objets en métal
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 10 - Appareils et instruments médicaux
  • 20 - Meubles et produits décoratifs
  • 39 - Services de transport, emballage et entreposage; organisation de voyages
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Retail store services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; wholesale services featuring pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; import-exports agencies in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; distribution of advertising materials and samples in the field of pharmaceuticals, pharmaceutical preparations and supplements, medicinal preparations and supplements, medical apparatus and instruments; business administration; business project management; advertising, marketing and promotional services; administration of businesses; business planning; administration relating to business planning; administration relating to marketing; business advisory services; business advisory services relating to product development; business advisory services relating to the management of businesses; business advice relating to advertising; dissemination of advertising material; dissemination of advertising matter; disseminating business, consumer, or commercial information in the field of pharmaceuticals, production and consumption; advertising; consulting services relating to marketing, advertising, promotion, brand development, business strategy, business and brand design, business communications and tracking and analysis of market trends; analysing and compiling business data for marketing intelligence purposes; business analysis services; business administration and management of shareholder and investor relations; providing shareholder business or commercial record keeping and business information and analysis; businesses development, management and operation services in the pharmaceutical and healthcare industries; intermediary business services relating to the commercialisation of goods; technology transfer services (business services); promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; marketing of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business intermediary services for the sale and purchase of goods and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; business information services; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing advertising information featuring goods and services of others for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma via an on-line searchable database; business advisory services relating to the commercialisation of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; chemical products for industrial, scientific and research purposes, namely, chemical reagents and chemical preparations for industrial, scientific and research purposes; fissionable chemical elements, namely, chemicals for use in industry and science and chemical substances for analyses in laboratories, other than for medical or veterinary purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive standard preparations in the nature of radionuclides and radioactive elements for the calibration of apparatus and machinery; diagnostic preparations, other than for medical or veterinary purposes; isotopes for industrial purposes; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical reagents, other than for medical or veterinary purposes; chemicals for use in the manufacture of radiopharmaceutical products; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anti-carcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for the treatment of cancers; pharmaceutical preparations and substances for diagnosis of cancers; pharmaceutical preparations and substances for therapy and treatment of cancers; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations for pharmaceutical use, namely, for the diagnosis and treatment of cancers; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; pharmaceutical preparations for the diagnosis of cancers; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemical preparations for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; reagents for medical purposes; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances in the nature of contrasting agents for medical imaging; diagnostic scanning reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemical preparations and reagents for medical purposes Containers of metal for storage of goods; containers of metal for medical waste; containers of metal for storing and transporting radioactive elements, products and materials; containers of metal for storing and transporting radioactive products; containers of metal for storing and transporting medical goods, apparatus and devices; containers of metal for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; parts and fittings for the aforesaid goods Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radioprotectors; custom manufacture of radiotherapy apparatus, devices and instruments; custom manufacture of apparatus, devices and instruments for medical purposes; custom manufacture of apparatus, devices and instruments for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services Radiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; instruments and apparatus for immunotherapy and immuno-diagnostics; medical devices, namely, blood analyzers; diagnostic devices for medical purposes, namely, medical imaging and detection devices; electrodes for medical purposes; injection syringes; instrument cases fitted for medical instruments for use by doctors and surgeons; special cases fitted for medical instruments; masks for medical staff, namely, surgical masks and protective face masks for medical use; pumps for medical purposes, namely, vacuum pumps for medical purposes; radiological apparatus for medical purposes; special containers for medical waste; storage and transport containers especially adapted for protection against ionising radiation for medical use; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; medical containers especially designed to maintain a consistent internal temperature; temperature controlled packaging specifically adapted for the transportation of pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; temperature controlled medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood and blood products, bio-technological medical and diagnostic medical products; refrigerated medical containers for storage, transportation and cooling of medicines, pharmaceuticals, radiopharmaceuticals, organs, blood, blood products, medical supplies, medical products, bio-technological products and diagnostic products; devices for detecting ionising radiation for medical use; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; nuclear medical tomographic scanner; diagnostic imaging apparatus for nuclear medicine; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; medical apparatus for the treatment of cancer; diagnostic imaging apparatus for medical use; pharmaceutical instruments, namely, radiological apparatus for medical purposes, medical apparatus for the treatment of cancer and diseases associated with cellular proliferation, and imaging apparatus for medical use for diagnosing medical conditions; applicators for pharmaceutical preparations, namely, applicators for pharmaceutical preparations sold without medication; medical apparatus for administering radiopharmaceutical diagnostic products; parts and fittings for the aforesaid goods Non-metallic containers, namely, containers for industrial and commercial liquids not made of metal; non-metallic containers for storing and transporting radioactive elements, products and materials; non-metallic containers for storing and transporting radioactive products; non-metallic containers for storing and transporting medical goods, apparatus and devices; non-metallic containers for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; structural foam containers for storage or transport; containers for transport, not of metal; parts and fittings for the aforesaid goods Supply chain logistics and reverse logistics services, namely, storage, transportation and delivery of goods for others by air, rail, ship or truck; supply chain logistics and reverse logistics services, namely, the storage, transportation and delivery of pharmaceuticals, radiopharmaceuticals, pharmaceutical and radiopharmaceuticals products for others by air, rail, ship or truck; packaging for transportation of clinical, pharmaceutical, radiopharmaceutical and health care products to the order and specification of others; leasing of temperature controlled cases for storage and transportation purposes; rental of insulated shipping containers for transporting temperature controlled materials; rental of insulated shipping containers for transporting room temperature, chilled, and frozen materials; providing information, consultancy and advisory services in relation to the aforementioned services Pharmaceutical, medicinal, veterinary and therapeutic research and development; pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services, namely, scientific research, analysis, testing, and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for medical use; scientific laboratory services; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; scientific research in the nature of conducting clinical trials in the field of oncology; scientific research in the nature of conducting clinical trials for others, namely, conducting phase clinical trials with target radiopharmaceuticals; medical and scientific research, namely, conducting clinical and pre-clinical trial services for others; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; research services in the fields of magnetic resonance and molecular imaging; medical research services relating to the development of radiotherapeutics and precision oncology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing and analysis of medical images; pathology services in support of drug development; pathology services for preclinical biomarker discovery research and clinical trials; hosting of a medical imaging analysis and visualization platform through a global computer network; hosting of a database of medical images; software as a service (SaaS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals, radiopharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blind independent central review of radiology images in the medical research and clinical trial setting; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in pharmaceutical and radiopharmaceutical drug research in the field of drug discovery; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; providing nondownloadable web-based computer software for database management in the fields of medical research, medical imaging, pharmaceutical, radiopharmaceutical and biotechnology research; research and development of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, medicines, pharmaceutical packaging and drug delivery technologies; research and development of new products for others; product development consultation; product research services, including, providing analytical testing, biosafety testing, reporting and laboratory services for others; preparation of scientific reports; scientific and technical consulting and research services for the pharmaceutical industry; consultation in the field of pharmaceutical drug delivery and dosage technologies; scientific and medical research and product design in relation to positron emission tomography imaging; scientific and medical research and product design in relation to single photon emission tomography imaging; design and development services; design and development of containers for the storage and transport of radioactive materials, radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, nonHodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; medical and scientific research in relation to disease diagnosis; scientific and medical research in relation to molecular imaging; development of molecular imaging products, development of non-medical molecular imaging services; diagnostic imaging for scientific purposes; scientific imaging services; medical laboratory services; medical and pharmacological research services; providing information, advisory and consultancy services in relation to the aforementioned services Provision of medical, health care, wellness and nutrition services; provision of medical, health care, wellness and nutrition advice services in relation to the prevention, treatment, prophylaxis and management of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood- borne tumours, leukemia and melanoma; medical counseling services in the field of treatment, prophylaxis or prevention of medical conditions; mental health therapy services, namely, psychedelic therapy; psychotherapy; medical treatment and therapy incorporating virtual reality; pharmaceutical advisory services; alternative medicine services; providing information, consultancy and advisory services in relation to the aforementioned services Licensing of technology, namely, patent and confidential information licensing of radiopharmaceutical preparations, technologies and apparatus; patent licensing; licensing of intellectual property; legal services relating to the exploitation of intellectual property rights; providing information, consultancy and advisory services in relation to the aforementioned services

15.

NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS

      
Numéro d'application 18498744
Statut En instance
Date de dépôt 2023-10-31
Date de la première publication 2024-06-13
Propriétaire Clarity Pharmaceuticals Ltd. (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Classes IPC  ?

  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/04 - Composés organiques
  • A61K 51/08 - Peptides, p. ex. protéines

16.

COMPOUNDS FOR RADIOIMAGING AND TREATMENT OF A CANCER

      
Numéro d'application AU2023051143
Numéro de publication 2024/098115
Statut Délivré - en vigueur
Date de dépôt 2023-11-10
Date de publication 2024-05-16
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Van Dam, Ellen Marianne
  • Mcinnes, Lachlan Eion

Abrégé

The present invention relates to compounds that inhibit fibroblast activation protein (FAP) and their uses in the treatment, prevention and/or imaging of a cancer associated with the expression of fibroblast activation protein.

Classes IPC  ?

  • A61K 51/04 - Composés organiques
  • A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
  • A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique

17.

IDENTIFICATION AND/OR TREATMENT OF CANCER

      
Numéro d'application AU2023051077
Numéro de publication 2024/086891
Statut Délivré - en vigueur
Date de dépôt 2023-10-26
Date de publication 2024-05-02
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Lengyelova, Eva
  • Van Dam, Ellen Marianne
  • Miller, Robert

Abrégé

The present invention relates generally to the identification and/or treatment of cancer and in particular cancers in which gastrin releasing peptide receptor (GRPR) is expressed. In particular embodiments, the present invention relates to the identification and/or treatment of prostate cancer and in particular GRPR expressing metastatic castrate resistance prostate cancer.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 9/08 - Solutions
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
  • A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
  • A61P 35/00 - Agents anticancéreux
  • C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
  • G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif

18.

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES

      
Numéro de document 03265005
Statut En instance
Date de dépôt 2023-08-16
Date de disponibilité au public 2024-02-22
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Ironside, Michael David

Classes IPC  ?

  • A61K 9/08 - Solutions
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
  • A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
  • A61K 51/08 - Peptides, p. ex. protéines

19.

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES

      
Numéro d'application AU2023050776
Numéro de publication 2024/036372
Statut Délivré - en vigueur
Date de dépôt 2023-08-16
Date de publication 2024-02-22
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Ironside, Michael David

Abrégé

The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging. Specifically, the present invention relates to aqueous formulations of 67 Cu radiolabelled compounds of Formula (I) further comprising a buffer, gentisic acid, ethanol and ascorbic acid for use in radiotherapy and diagnostic imaging.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 9/08 - Solutions
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
  • A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
  • A61P 35/00 - Agents anticancéreux

20.

DIMERIC RADIOPHARMACEUTICALS, COMPOSITIONS THEREOF AND USES THEREOF

      
Numéro d'application AU2023050761
Numéro de publication 2024/031153
Statut Délivré - en vigueur
Date de dépôt 2023-08-11
Date de publication 2024-02-15
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Van Dam, Ellen Marianne
  • Mcinnes, Lachlan Eion

Abrégé

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.

Classes IPC  ?

  • A61K 51/04 - Composés organiques
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 33/34 - CuivreSes composés
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61P 35/00 - Agents anticancéreux
  • C07D 487/08 - Systèmes pontés
  • C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides

21.

Radiopharmaceuticals, uses thereof, and methods for the production thereof

      
Numéro d'application 18021252
Statut En instance
Date de dépôt 2021-08-13
Date de la première publication 2024-02-15
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Donnelly, Paul Stephen
  • Van Dam, Ellen Marianne
  • Harris, Matthew John

Abrégé

Radiopharmaceutical compounds of general Formula (I) are based on a sarcophagine cage having a PEG linker-group X through to a group Y capable of binding to a biological receptor and an albumin-binding group Z for the treatment, diagnosis or imaging of diseases including cancer, and the production of such compounds and their complexes. Radiopharmaceutical compounds of general Formula (I) are based on a sarcophagine cage having a PEG linker-group X through to a group Y capable of binding to a biological receptor and an albumin-binding group Z for the treatment, diagnosis or imaging of diseases including cancer, and the production of such compounds and their complexes.

Classes IPC  ?

22.

Radiopharmaceuticals, radioimaging agents, and uses thereof

      
Numéro d'application 18233135
Numéro de brevet 12234242
Statut Délivré - en vigueur
Date de dépôt 2023-08-11
Date de la première publication 2023-11-30
Date d'octroi 2025-02-25
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Zia, Nicholas Alan
  • Donnelly, Paul Stephen

Abrégé

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

  • C07D 487/08 - Systèmes pontés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 33/34 - CuivreSes composés
  • A61K 51/04 - Composés organiques
  • A61K 51/06 - Composés macromoléculaires
  • C07F 1/08 - Composés du cuivre
  • C07F 1/00 - Composés contenant des éléments des groupes 1 ou 11 du tableau périodique

23.

FORMULATIONS AND KITS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING

      
Numéro d'application 18339124
Statut En instance
Date de dépôt 2023-06-21
Date de la première publication 2023-10-19
Propriétaire Clarity Pharmaceuticals Limited (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Lumb, Sean

Abrégé

Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer. Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.

Classes IPC  ?

24.

COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER

      
Numéro d'application AU2022051410
Numéro de publication 2023/092184
Statut Délivré - en vigueur
Date de dépôt 2022-11-24
Date de publication 2023-06-01
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Harris, Matthew John
  • Van Dam, Ellen Marianne
  • Biggin, Colin

Abrégé

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to PSMA, compositions thereof and uses thereof in methods of treatment.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • A61P 35/00 - Agents anticancéreux
  • C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
  • C07K 7/02 - Peptides linéaires contenant au moins une liaison peptidique anormale

25.

RADIOPHARMACEUTICALS, METHODS FOR THE PRODUCTION THEREOF, AND USES IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES

      
Numéro d'application AU2022050905
Numéro de publication 2023/019303
Statut Délivré - en vigueur
Date de dépôt 2022-08-16
Date de publication 2023-02-23
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Donnelly, Paul Stephen
  • Ironside, Michael David

Abrégé

The present invention relates to compounds that can complex a radionuclide and formulations and kits comprising compounds that can complex a radionuclide. The compounds, formulations and kits are of use in radiotherapy and diagnostic imaging.

Classes IPC  ?

  • C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
  • C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61P 35/00 - Agents anticancéreux

26.

RADIOLABELLED TARGETING LIGANDS

      
Numéro d'application 17775150
Statut En instance
Date de dépôt 2020-11-06
Date de la première publication 2023-02-02
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Thurecht, Kristofer James
  • Soh Ying Yi, Vanessa
  • Blakey, Idriss
  • Musthakahmed, Muneer Ahamed Syed
  • Harris, Matthew
  • Van Dam, Ellen

Abrégé

The present invention relates to compounds that are useful as radioimaging agents and radiopharmaceuticals. The compounds may be coordinated with a radionuclide and may be useful in diagnostic imaging and radiotherapy. The invention also relates to methods of prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

27.

FORMULATIONS OF PSMA IMAGING AGENTS

      
Numéro d'application 17594991
Statut En instance
Date de dépôt 2020-05-22
Date de la première publication 2022-10-06
Propriétaire Clarity Pharmaceuticals Limited (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Zia, Nicholas Alan
  • Spare, Lawson Kyle
  • Van Dam, Ellen Marianne
  • Kuan, Kevin Kar Weng

Abrégé

The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA).

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 51/04 - Composés organiques
  • A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
  • A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
  • C07F 1/08 - Composés du cuivre

28.

Radiopharmaceuticals, radioimaging agents, and uses thereof

      
Numéro d'application 17834773
Numéro de brevet 11970503
Statut Délivré - en vigueur
Date de dépôt 2022-06-07
Date de la première publication 2022-10-06
Date d'octroi 2024-04-30
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Zia, Nicholas Alan
  • Donnelly, Paul Stephen

Abrégé

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

  • C07D 487/08 - Systèmes pontés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 33/34 - CuivreSes composés
  • A61K 51/04 - Composés organiques
  • A61K 51/06 - Composés macromoléculaires
  • C07F 1/08 - Composés du cuivre
  • C07F 1/00 - Composés contenant des éléments des groupes 1 ou 11 du tableau périodique

29.

RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF

      
Numéro d'application AU2021050896
Numéro de publication 2022/032353
Statut Délivré - en vigueur
Date de dépôt 2021-08-13
Date de publication 2022-02-17
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Mcinnes, Lachlan Eion
  • Donnelly, Paul Stephen
  • Van Dam, Ellen Marianne
  • Harris, Matthew John

Abrégé

Radiopharmaceutical compounds of general Formula (I) are based on a sarcophagine cage having a PEG linker-group X through to a group Y capable of binding to a biological receptor and an albumin-binding group Z for the treatment, diagnosis or imaging of diseases including cancer, and the production of such compounds and their complexes.

Classes IPC  ?

  • A61K 51/08 - Peptides, p. ex. protéines
  • C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
  • C07K 5/12 - Peptides cycliques
  • C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
  • A61P 35/00 - Agents anticancéreux

30.

Radiopharmaceuticals, radioimaging agents, and uses thereof

      
Numéro d'application 17198131
Numéro de brevet 11384088
Statut Délivré - en vigueur
Date de dépôt 2021-03-10
Date de la première publication 2022-02-10
Date d'octroi 2022-07-12
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Zia, Nicholas Alan
  • Donnelly, Paul Stephen

Abrégé

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

  • C07D 487/08 - Systèmes pontés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 33/34 - CuivreSes composés
  • A61K 51/04 - Composés organiques
  • A61K 51/06 - Composés macromoléculaires
  • C07F 1/08 - Composés du cuivre
  • C07F 1/00 - Composés contenant des éléments des groupes 1 ou 11 du tableau périodique

31.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

      
Numéro d'application 17393837
Numéro de brevet 11905301
Statut Délivré - en vigueur
Date de dépôt 2021-08-04
Date de la première publication 2021-11-25
Date d'octroi 2024-02-20
Propriétaire Clarity Pharmaceuticals Ltd. (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Classes IPC  ?

  • A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/04 - Composés organiques
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 49/10 - Composés organiques
  • A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
  • A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support
  • A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments

32.

RADIOLABELLED TARGETING LIGANDS

      
Numéro d'application AU2020051209
Numéro de publication 2021/087568
Statut Délivré - en vigueur
Date de dépôt 2020-11-06
Date de publication 2021-05-14
Propriétaire
  • THE UNIVERSITY OF QUEENSLAND (Australie)
  • CLARITY PHARMACEUTICALS LTD. (Australie)
Inventeur(s)
  • Thurecht, Kristofer James
  • Soh Ying Yi, Vanessa
  • Blakey, Idriss
  • Musthakahmed, Muneer Ahamed Syed
  • Harris, Matthew
  • Van Dam, Ellen

Abrégé

The present invention relates to compounds that are useful as radioimaging agents and radiopharmaceuticals. The compounds may be coordinated with a radionuclide and may be useful in diagnostic imaging and radiotherapy. The invention also relates to methods of prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

33.

Targeting compounds and methods for their production

      
Numéro d'application 17046053
Numéro de brevet 11951189
Statut Délivré - en vigueur
Date de dépôt 2019-04-11
Date de la première publication 2021-02-04
Date d'octroi 2024-04-09
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Zia, Nicholas Alan

Abrégé

The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.

Classes IPC  ?

  • A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
  • A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
  • A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
  • A61K 51/04 - Composés organiques
  • C07D 487/08 - Systèmes pontés

34.

Formulations and kits for radiotherapy and diagnostic imaging

      
Numéro d'application 17042772
Numéro de brevet 11738100
Statut Délivré - en vigueur
Date de dépôt 2019-04-11
Date de la première publication 2021-01-21
Date d'octroi 2023-08-29
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Lumb, Sean

Abrégé

Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.

Classes IPC  ?

  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61M 36/14 - Pansements radioactifs
  • A61K 51/04 - Composés organiques
  • A61K 9/08 - Solutions
  • A61K 49/10 - Composés organiques
  • A61P 35/00 - Agents anticancéreux
  • A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
  • A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines

35.

FORMULATIONS OF PSMA IMAGING AGENTS

      
Numéro de document 03137773
Statut En instance
Date de dépôt 2020-05-22
Date de disponibilité au public 2020-12-03
Propriétaire CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Zia, Nicholas Alan
  • Spare, Lawson Kyle
  • Van Dam, Ellen Marianne
  • Kuan, Kevin Kar Weng

Abrégé

The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA). There is provided an aqueous formulation for parenteral administration comprising a compound of Formula (I), or a salt thereof, complexed with a Cu ion, Formulations disclosed herein may include gentisic acid or a salt thereof, and ascorbic acid or a salt thereof. The Cu ion may be a Cu radioisotope.

Classes IPC  ?

36.

FORMULATIONS OF PSMA IMAGING AGENTS

      
Numéro d'application AU2020050509
Numéro de publication 2020/237290
Statut Délivré - en vigueur
Date de dépôt 2020-05-22
Date de publication 2020-12-03
Propriétaire
  • THE UNIVERSITY OF MELBOURNE (Australie)
  • CLARITY PHARMACEUTICALS LIMITED (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Zia, Nicholas Alan
  • Spare, Lawson Kyle
  • Van Dam, Ellen Marianne
  • Kuan, Kevin Kar Weng

Abrégé

The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA).

Classes IPC  ?

37.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

      
Numéro d'application 16712485
Numéro de brevet 11111254
Statut Délivré - en vigueur
Date de dépôt 2019-12-12
Date de la première publication 2020-04-16
Date d'octroi 2021-09-07
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Classes IPC  ?

  • A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/04 - Composés organiques
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 49/10 - Composés organiques
  • A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
  • A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support
  • A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments

38.

Radiopharmaceuticals, radioimaging agents, and uses thereof

      
Numéro d'application 16619073
Numéro de brevet 10975089
Statut Délivré - en vigueur
Date de dépôt 2018-06-05
Date de la première publication 2020-03-26
Date d'octroi 2021-04-13
Propriétaire Clarity Pharmaceuticals Ltd (Australie)
Inventeur(s)
  • Zia, Nicholas Alan
  • Donnelly, Paul Stephen

Abrégé

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Classes IPC  ?

  • C07D 487/08 - Systèmes pontés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 33/34 - CuivreSes composés
  • A61K 51/04 - Composés organiques
  • A61K 51/06 - Composés macromoléculaires
  • C07F 1/08 - Composés du cuivre
  • C07F 1/00 - Composés contenant des éléments des groupes 1 ou 11 du tableau périodique

39.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

      
Numéro d'application 16378716
Numéro de brevet 10870664
Statut Délivré - en vigueur
Date de dépôt 2019-04-09
Date de la première publication 2019-07-25
Date d'octroi 2020-12-22
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Classes IPC  ?

  • A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/04 - Composés organiques
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 49/10 - Composés organiques
  • A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
  • A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support
  • A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments

40.

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING

      
Numéro de document 03042737
Statut En instance
Date de dépôt 2017-11-02
Date de disponibilité au public 2018-05-11
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Harris, Matthew John
  • Van Dam, Ellen Marianne
  • Jeffery, Charmaine Marie

Abrégé

The present invention relates to stable formulations of Formula (I), or a salt thereof, complexed with a Cu ion, that are of use in radiotherapy, diagnostic imaging and cancer treatment, wherein the formulations minimize dissociation of the radioisotope from the ligand and/or minimize radiolysis of the ligand arising from the radioisotope.

Classes IPC  ?

41.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

      
Numéro d'application 15612009
Numéro de brevet 10544164
Statut Délivré - en vigueur
Date de dépôt 2017-06-02
Date de la première publication 2017-09-21
Date d'octroi 2020-01-28
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Classes IPC  ?

  • A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/04 - Composés organiques
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 49/10 - Composés organiques
  • A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
  • A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support

42.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

      
Numéro d'application 15612185
Numéro de brevet 10301326
Statut Délivré - en vigueur
Date de dépôt 2017-06-02
Date de la première publication 2017-09-21
Date d'octroi 2019-05-28
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilizing the radiolabelled compounds of the invention.

Classes IPC  ?

  • A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/04 - Composés organiques
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 49/10 - Composés organiques
  • A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
  • A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support

43.

Cage amine ligands for metallo-radiopharmaceuticals

      
Numéro d'application 15240836
Numéro de brevet 09861714
Statut Délivré - en vigueur
Date de dépôt 2016-08-18
Date de la première publication 2016-12-08
Date d'octroi 2018-01-09
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul
  • Paterson, Brett

Abrégé

The present invention relates to compounds that are useful as metal ligands and which can be bound to a biological entity such as a molecular recognition moiety and methods of making these compounds. Once the compounds that are bound to a biological entity are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilizing the radiolabelled compounds of the invention.

Classes IPC  ?

44.

Functionalisation of cage amine ligands for metallo-radiopharmaceuticals

      
Numéro d'application 14363242
Numéro de brevet 09364570
Statut Délivré - en vigueur
Date de dépôt 2012-12-06
Date de la première publication 2015-02-19
Date d'octroi 2016-06-14
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul
  • Paterson, Brett

Abrégé

The present invention relates to compounds that are useful as metal ligands and which contain a moiety capable of binding to a biological entity and methods of making these compounds. These compounds are of interest as they can be bound to a biological entity and then coordinated with a suitable metallic radionuclide. The coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging.

Classes IPC  ?

  • A61K 51/04 - Composés organiques
  • C07D 487/08 - Systèmes pontés
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

45.

Cage amine ligands for metallo-radiopharmaceuticals

      
Numéro d'application 14363219
Numéro de brevet 09457107
Statut Délivré - en vigueur
Date de dépôt 2012-12-06
Date de la première publication 2014-10-30
Date d'octroi 2016-10-04
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul
  • Paterson, Brett

Abrégé

The present invention relates to compounds that are useful as metal ligands and which can be bound to a biological entity such as a molecular recognition moiety and methods of making these compounds. Once the compounds that are bound to a biological entity are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilizing the radiolabelled compounds of the invention.

Classes IPC  ?

46.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

      
Numéro d'application 13132194
Numéro de brevet 09701694
Statut Délivré - en vigueur
Date de dépôt 2009-12-02
Date de la première publication 2011-12-01
Date d'octroi 2017-07-11
Propriétaire CLARITY PHARMACEUTICALS LTD (Australie)
Inventeur(s)
  • Donnelly, Paul Stephen
  • Ma, Michelle Therese
  • Scanlon, Denis Bernard

Abrégé

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Classes IPC  ?

  • A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
  • C07D 521/00 - Composés hétérocycliques contenant des hétérocycles non spécifiés
  • A61K 51/08 - Peptides, p. ex. protéines
  • A61K 51/04 - Composés organiques
  • A61K 49/10 - Composés organiques
  • A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
  • A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
  • A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
  • A61K 51/02 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par le support